ESHRE指南:IVF/ICSI中移植胚胎数量的选择
该指南由ESHRE制定,基于截至2023年5月的文献,提供35条推荐(25条循证推荐,其中24条为强推荐、1条为条件推荐,10条良好实践要点),核心结论为:无任何临床或胚胎学因素本身足以推荐双胚胎移植(DET)替代选择性单胚胎移植(eSET)。
要点
- 无临床或胚胎学因素本身足以推荐DET替代eSET。
- 指南共35条推荐:25条循证推荐(24条强推荐、1条条件推荐),10条良好实践要点。
- 7条(28%)循证推荐基于中等质量证据,3条(12%)基于低质量证据,15条(60%)基于极低质量证据。
核心结论
- 无任何临床或胚胎学因素本身足以推荐在IVF/ICSI中采用双胚胎移植(DET)替代选择性单胚胎移植(eSET)。
研究设计与样本
- 该指南按照ESHRE指南制定与更新的结构化方法制定,检索PUBMED/MEDLINE和Cochrane数据库,纳入截至2023年5月发表的英文相关论文。
- 关键结局包括活产率、累积活产率和多胎妊娠率。
- 指南制定组(GDG)基于收集的证据讨论推荐直至达成共识,草案定稿后组织利益相关者评审,最终版经GDG和ESHRE执行委员会批准。
主要发现
- 指南就多胎妊娠相关的医学和非医学风险以及决定移植胚胎数量时应考虑的临床和胚胎学因素提供35条推荐。
- 35条推荐包括25条循证推荐(24条为强推荐,1条为条件推荐)和10条良好实践要点。
- 25条循证推荐中,7条(28%)有中等质量证据支持,3条(12%)有低质量证据支持,15条(60%)有极低质量证据支持。
关键数值与推荐
- 指南提供35条推荐:25条循证推荐(24条强推荐、1条条件推荐)和10条良好实践要点。
- 25条循证推荐中,7条(28%)基于中等质量证据,3条(12%)基于低质量证据,15条(60%)基于极低质量证据。
临床怎么用
- 指南为卫生专业人员提供基于当前最佳证据的IVF/ICSI决策过程最佳实践明确建议,以及应向患者传达的相关信息建议。
- 指南还提供研究建议清单以促进该领域进一步研究。
局限性
- 该指南基于现有证据逐一评估不同因素,但现实中临床医生的决策基于与每位患者病例相关的多个预后因素。
- 随机对照试验证据太少,无法制定高质量循证推荐。
- 由于缺乏循证研究,指南还明确提及对未来研究的建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Which clinical and embryological factors should be considered to apply double embryo transfer (DET) instead of elective single embryo transfer (eSET)? SUMMARY ANSWER: No clinical or embryological factor per se justifies a recommendation of DET instead of eSET in IVF/ICSI. WHAT IS KNOWN ALREADY: DET is correlated with a higher rate of multiple pregnancy, leading to a subsequent increase in complications for both mother and babies. These complications include preterm birth, low birthweight, and other perinatal adverse outcomes. To mitigate the risks associated with multiple pregnancy, eSET is recommended by international and national professional organizations as the preferred approach in ART. STUDY DESIGN, SIZE, DURATION: The guideline was developed according to the structured methodology for development and update of ESHRE guidelines. Literature searches were performed in PUBMED/MEDLINE and Cochrane databases, and relevant papers published up to May 2023, written in English, were included. Live birth rate, cumulative live birth rate, and multiple pregnancy rate were considered as critical outcomes. PARTICIPANTS/MATERIALS, SETTING, METHODS: Based on the collected evidence, recommendations were discussed until a consensus was reached within the Guideline Development Group (GDG). A stakeholder review was organized after the guideline draft was finalized. The final version was approved by the GDG and the ESHRE Executive Committee. MAIN RESULTS AND THE ROLE OF CHANCE: The guideline provides 35 recommendations on the medical and non-medical risks associated with multiple pregnancies and on the clinical and embryological factors to be considered when deciding on the number of embryos to transfer. These recommendations include 25 evidence-based recommendations, of which 24 were formulated as strong recommendations and one as conditional, and 10 good practice points. Of the evidence-based recommendations, seven (28%) were supported by moderate-quality evidence. The remaining recommendations were supported by low (three recommendations; 12%), or very low-quality evidence (15 recommendations; 60%). Owing to the lack of evidence-based research, the guideline also clearly mentions recommendations for future studies. LIMITATIONS, REASONS FOR CAUTION: The guideline assessed different factors one by one based on existing evidence. However, in real life, clinicians' decisions are based on several prognostic factors related to each patient's case. Furthermore, the evidence from randomized controlled trials is too scarce to formulate high-quality evidence-based recommendations. WIDER IMPLICATIONS OF THE FINDINGS: The guideline provides health professionals with clear advice on best practice in the decision-making process during IVF/ICSI, based on the best evidence currently available, and recommendations on relevant information that should be communicated to patients. In addition, a list of research recommendations is provided to stimulate further studies in the field. STUDY FUNDING/COMPETING INTEREST(S): The guideline was developed and funded by ESHRE, covering expenses associated with the guideline meetings, the literature searches, and the dissemination of the guideline. The guideline group members did not receive payment. DPB declared receiving honoraria for lectures from Merck, Ferring, and Gedeon Richter. She is a member of ESHRE EXCO, and the Mediterranean Society for reproductive medicine and the president of the Croatian Society for Gynaecological Endocrinology and Reproductive Medicine. CDG is the past Chair of the ESHRE EIM Consortium and a paid deputy member of the Editorial board of Human Reproduction. IR declared receiving reimbursement from ESHRE and EDCD for attending meetings. She holds an unpaid leadership role in OBBCSSR, ECDC Sohonet, and AER. KAR-W declared receiving grants for clinical researchers and funding provision to the institution from the Swedish Cancer Society (200170F), the Senior Clinical Investigator Award, Radiumhemmets Forskningsfonder (Dnr: 201313), Stockholm County Council FoU (FoUI-953912) and Karolinska Institutet (Dnr 2020-01963), NovoNordisk, Merck and Ferring Pharmaceuticals. She received consulting fees from the Swedish Ministry of Health and Welfare. She received honoraria from Roche, Pfizer, and Organon for chairmanship and lectures. She received support from Organon for attending meetings. She participated in advisory boards for Merck, Nordic countries, and Ferring. She declared receiving time-lapse equipment and grants with payment to institution for pre-clinical research from Merck pharmaceuticals and from Ferring. SS-R received research funding from Roche Diagnostics, Organon/MSD, Theramex, and Gedeo-Richter. He received consulting fees from Organon/MSD, Ferring Pharmaceuticals, and Merck Serono. He declared receiving honoraria for lectures from Ferring Pharmaceuticals, Besins, Organon/MSD, Theramex, and Gedeon Richter. He received support for attending Gedeon Richter meetings and participated in the Data Safety Monitoring Board of the T-TRANSPORT trial. He is the Deputy of ESHRE SQART special interest group. He holds stock options in IVI Lisboa and received equipment and other services from Roche Diagnostics and Ferring Pharmaceuticals. KT declared receiving payment for honoraria for giving lectures from Merck Serono and Organon. She is member of the safety advisory board of EDQM. She holds a leadership role in the ICCBBA board of directors. ZV received reimbursement from ESHRE for attending meetings. She also received research grants from ESHRE and Juhani Aaltonen Foundation. She is the coordinator of EHSRE SQART special interest group. The other authors have no conflicts of interest to declare. DISCLAIMER: This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. Adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not replace the need for application of clinical judgement to each individual presentation, nor variations based on locality and facility type. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose (full disclaimer available at https://www.eshre.eu/Guidelines-and-Legal).
引用
- Alteri A, Arroyo G, Baccino G, et al. ESHRE guideline: number of embryos to transfer during IVF/ICSI†. Hum Reprod. 2024. PMID: 38364208. doi:10.1093/humrep/deae010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。